CD274 and non-small cell lung carcinoma: In that manner, a strong anti-tumor effect in vivo was also shown by a peptide (PD-1-Vaxx) residing at the position 92–101 of hPD-1 [123]; the safety, tolerability and immunogenicity of the peptide as monotherapy in patients with PD-L1 expressing non-small cell lung cancer (NSCLC) is being evaluated in a phase I clinical trial [124].